Anivive Lifesciences Receives Contract From Nih To Utilize Science Behind Valley Fever Vaccine

WEB Anivive Lifesciences Inc Unveils Groundbreaking Research on Systemic Vaccine

Anivive Lifesciences Receives Contract from NIH to Utilize Science Behind Valley Fever Vaccine

WEB Anivive Lifesciences, a One Health technology company, has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID) to utilize the underlying science in Anivive's animal health Valley Fever vaccine for the development of a systemic human vaccine against Valley Fever.

WEB Anivive Lifesciences is set to unveil groundbreaking research at the upcoming World Vaccine Congress, providing insights into the mechanism of action of its preclinical Valley Fever vaccine. The presentation by Dr. Robb will shed light on the vaccine's potential to revolutionize the prevention and treatment of Valley Fever in both animals and humans.

WEB This contract funding aims to harness the scientific advancements made in Anivive's animal health Valley Fever vaccine to develop a systemic human vaccine against Valley Fever. Valley Fever is a serious fungal infection that affects both animals and humans, and there is currently no approved human vaccine available.

WEB Anivive Lifesciences is committed to One Health, which recognizes the interconnectedness of human, animal, and environmental health. The company's work in both animal and human health demonstrates its dedication to improving the well-being of all species and advancing scientific innovation.